Dishman Carbogen Amcis Limited announced its audited consolidated financial results for the quarter ended March 31, 2026, alongside other corporate updates including the approval of an External Commercial Borrowing (ECB) of up to CHF 200 million from a promoter group company. The company reported a consolidated net profit of ₹21.74 crores for the quarter ended March 31, 2026, compared to a net loss of ₹12.97 crores in the previous quarter (ended December 31, 2025) and a net profit of ₹43.09 crores in the corresponding quarter of the previous year (ended March 31, 2025). Total income from operations stood at ₹851.40 crores for the current quarter, compared to ₹719.80 crores in the preceding quarter and ₹716.34 crores in the corresponding quarter of the previous year.

Dishman Carbogen Amcis Limited (DCAL) is a global, fully integrated Contract Development and Manufacturing Organization (CDMO) that provides end-to-end solutions for the pharmaceutical and biopharmaceutical industries. Founded in 1983 and headquartered in Ahmedabad, India, the company specializes in complex chemical synthesis, High Potent Active Pharmaceutical Ingredients (HiPo APIs), and Vitamin D analogues, supporting clients from early-stage clinical development through commercialization. The company maintains an extensive global footprint with manufacturing facilities and R&D centers located across India, Switzerland, the UK, France, China, and the Netherlands. In early 2026, the company successfully completed an unannounced GMP inspection of its Shanghai facility by the National Medical Products Administration (NMPA) with no observations. Additionally, in late 2025 and early 2026, DCAL engaged in various capital-raising activities, including the allotment of Non-Convertible Debentures (NCDs) to support its operations and financial requirements.